<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087516</url>
  </required_header>
  <id_info>
    <org_study_id>0431-021</org_study_id>
    <secondary_id>Formally-C0604MT2D</secondary_id>
    <secondary_id>MK0431-021</secondary_id>
    <secondary_id>2006_413</secondary_id>
    <nct_id>NCT00087516</nct_id>
  </id_info>
  <brief_title>Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine the safety and efficacy of an
      investigational drug in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 104</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 104</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hr PMG at Week 104</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">741</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg/100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 200 mg/200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase A and B: Oral tablets of sitagliptin 200 mg q.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Sitagliptin 200 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin (MK0431)</intervention_name>
    <description>Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.</description>
    <arm_group_label>Sitagliptin 100 mg/100 mg</arm_group_label>
    <other_name>MK0431</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.</description>
    <arm_group_label>Sitagliptin 200 mg/200 mg</arm_group_label>
    <other_name>MK0431</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.</description>
    <arm_group_label>Placebo/Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.</description>
    <arm_group_label>Placebo/Sitagliptin 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin - Rescue</intervention_name>
    <description>Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.</description>
    <arm_group_label>Sitagliptin 100 mg/100 mg</arm_group_label>
    <arm_group_label>Sitagliptin 200 mg/200 mg</arm_group_label>
    <arm_group_label>Placebo/Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Placebo/Sitagliptin 200 mg</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus

          -  Patient is not pregnant or breastfeeding

          -  Male or female patient unlikely to conceive

          -  Patient not on an antihyperglycemic drug

        Exclusion Criteria:

          -  Patient has history of type 1 diabetes mellitus

          -  Patient has history of ketoacidosis

          -  Patient requires insulin within 8 weeks prior to start of study

          -  Patient on weight loss program and is not in maintenance phase

          -  Patient taking weight loss medication within 8 weeks prior to start of study

          -  Patient on or likely to require = 14 days or repeated courses of corticosteroids

          -  Patient taking immunosuppressive/immunomodulating medication

          -  Patient taking digoxin or other cardiac medication

          -  Patient has undergone surgical general anesthesia within 30 days prior to start of
             study

          -  Patient taking investigational drug within 8 weeks prior to start of study

          -  Patient is diagnosed with liver disease

          -  Patient has chronic myopathy, progressive neurological/neuromuscular disorder

          -  Patient has with severe cardiac conditions within the last 6 months

          -  Patient is Human immunodeficiency virus (HIV) positive

          -  Patient has hematological disorder

          -  Patient has history of malignancy

          -  Patient has history of alcohol or drug abuse within the past 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7.</citation>
    <PMID>17130196</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2004</study_first_submitted>
  <study_first_submitted_qc>July 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2004</study_first_posted>
  <results_first_submitted>May 10, 2010</results_first_submitted>
  <results_first_submitted_qc>May 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2010</results_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 08-Jul-2004; Last Patient Last Visit: 07-Feb-2007; One hundred eleven medical clinics worldwide (56 in the United States and Puerto Rico, 16 in 6 countries in Europe and 39 in 11 countries in the rest of the world).</recruitment_details>
      <pre_assignment_details>Patients 18-75 years not on an antihyperglycemic agent (AHA) or on oral single AHA or low-dose combination therapy were eligible to participate. Following a screening diet/exercise period of variable duration, patients with hemoglobin A1c (A1C) 7-10% were eligible to enter a 2-week placebo run-in/wash-off period prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg/100 mg</title>
          <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin 200 mg/200 mg</title>
          <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Sitagliptin 100 mg</title>
          <description>The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.</description>
        </group>
        <group group_id="P4">
          <title>Placebo/Sitagliptin 200 mg</title>
          <description>The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol specified discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient was non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recommendation of Primary Care Physician</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg</title>
          <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin 200 mg</title>
          <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="238"/>
            <count group_id="B2" value="250"/>
            <count group_id="B3" value="253"/>
            <count group_id="B4" value="741"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="9.5"/>
                    <measurement group_id="B2" value="54.9" spread="10.1"/>
                    <measurement group_id="B3" value="54.3" spread="10.1"/>
                    <measurement group_id="B4" value="54.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.7" spread="43.0"/>
                    <measurement group_id="B2" value="174.2" spread="46.2"/>
                    <measurement group_id="B3" value="176.1" spread="41.8"/>
                    <measurement group_id="B4" value="173.7" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (A1C)</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="0.9"/>
                    <measurement group_id="B2" value="8.1" spread="0.9"/>
                    <measurement group_id="B3" value="8.0" spread="0.8"/>
                    <measurement group_id="B4" value="8.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 24</title>
        <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
        <time_frame>Weeks 0-24</time_frame>
        <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 24</title>
          <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.</description>
          <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" lower_limit="-0.74" upper_limit="-0.49"/>
                    <measurement group_id="O2" value="-0.76" lower_limit="-0.88" upper_limit="-0.64"/>
                    <measurement group_id="O3" value="0.18" lower_limit="0.06" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline A1C</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline A1C</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 24</title>
        <description>Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
        <time_frame>Weeks 0-24</time_frame>
        <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 24</title>
          <description>Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.</description>
          <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="244"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" lower_limit="-17.4" upper_limit="-7.4"/>
                    <measurement group_id="O2" value="-16.6" lower_limit="-21.5" upper_limit="-11.7"/>
                    <measurement group_id="O3" value="4.7" lower_limit="-0.2" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline FPG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-17.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.1</ci_lower_limit>
            <ci_upper_limit>-10.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline FPG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-21.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.2</ci_lower_limit>
            <ci_upper_limit>-14.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24</title>
        <description>Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.</description>
        <time_frame>Weeks 0-24</time_frame>
        <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 or 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24</title>
          <description>Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.</description>
          <population>The all-patients-treated population included all patients with at least one dose of double-blind study therapy, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.9" lower_limit="-57.9" upper_limit="-40.0"/>
                    <measurement group_id="O2" value="-56.3" lower_limit="-65.2" upper_limit="-47.5"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-11.1" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline 2-hr PMG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-46.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-59.4</ci_lower_limit>
            <ci_upper_limit>-34.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment, presence/absence of prior diabetes pharmacotherapy, baseline 2-hr PMG</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-54.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-66.7</ci_lower_limit>
            <ci_upper_limit>-41.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 104</title>
        <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.</description>
        <time_frame>Weeks 0-104</time_frame>
        <population>The all-patients-treated population for Week 104 included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg/100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg/200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo/ Sitagliptin 100 mg</title>
            <description>The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin 200 mg</title>
            <description>The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 104</title>
          <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.</description>
          <population>The all-patients-treated population for Week 104 included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-0.41" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-0.53" upper_limit="-0.26"/>
                    <measurement group_id="O3" value="-0.32" lower_limit="-0.53" upper_limit="-0.11"/>
                    <measurement group_id="O4" value="-0.34" lower_limit="-0.55" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 104</title>
        <description>Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.</description>
        <time_frame>Weeks 0-104</time_frame>
        <population>The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg/100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg/200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Sitagliptin 100 mg</title>
            <description>The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin 200 mg</title>
            <description>The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 104</title>
          <description>Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.</description>
          <population>The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-7.3" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-11.1" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-4.1" lower_limit="-12.5" upper_limit="4.3"/>
                    <measurement group_id="O4" value="-4.1" lower_limit="-12.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hr PMG at Week 104</title>
        <description>Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.</description>
        <time_frame>Weeks 0-104</time_frame>
        <population>The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg/100 mg</title>
            <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin 200 mg/200 mg</title>
            <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Sitagliptin 100 mg</title>
            <description>The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Sitagliptin 200 mg</title>
            <description>The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hr PMG at Week 104</title>
          <description>Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.</description>
          <population>The all-patients-treated population for Week 104, included all patients with at least one dose of double-blind study therapy after Week 24, and with a baseline value and ≥1 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward method.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" lower_limit="-40.1" upper_limit="-21.0"/>
                    <measurement group_id="O2" value="-41.5" lower_limit="-51.0" upper_limit="-32.1"/>
                    <measurement group_id="O3" value="-38.3" lower_limit="-53.2" upper_limit="-23.4"/>
                    <measurement group_id="O4" value="-35.5" lower_limit="-50.9" upper_limit="-20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 0-104</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg/100 mg</title>
          <description>The Sitagliptin 100 mg/100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg q.d. (once daily) for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin 200 mg/200 mg</title>
          <description>The Sitagliptin 200 mg/200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 200 mg q.d. for up to 104 weeks (including the 24-week Phase A study period and 80-week Phase B study period).</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Sitagliptin 100 mg</title>
          <description>The Placebo/Sitagliptin 100 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 100 mg q.d. during the 80-week Phase B study period.</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Sitagliptin 200 mg</title>
          <description>The Placebo/Sitagliptin 200 mg group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo tablets once daily during the 24-week Phase A study period followed by oral tablets of sitagliptin 200 mg q.d. during the 80-week Phase B study period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Borderline Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Strangulated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gallbladder Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Of Salivary Gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bronchitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaesthetic Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Foreign Body Trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Radial Nerve Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Benign Renal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rectal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

